Skip Navigation


Carcinogenesis Advance Access originally published online on June 15, 2006
Carcinogenesis 2006 27(11):2141-2147; doi:10.1093/carcin/bgl101
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/11/2141    most recent
bgl101v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Brocke, J. v.
Right arrow Articles by Hollstein, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brocke, J. v.
Right arrow Articles by Hollstein, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

MEF immortalization to investigate the ins and outs of mutagenesis

Jochen vom Brocke, Heinz H. Schmeiser, Manuela Reinbold1 and Monica Hollstein1,*

Department of Molecular Toxicology, German Cancer Research Center (DKFZ, Deutsches Krebsforschungszentrum), Im Neuenheimer Feld 280 D69120 Heidelberg, Germany
1 Department of Genetic Alterations in Carcinogenesis, German Cancer Research Center (DKFZ, Deutsches Krebsforschungszentrum), Im Neuenheimer Feld 280 D69120 Heidelberg, Germany

*To whom correspondence should be addressed. Email: m.hollstein{at}dkfz-heidelberg.de

The importance of tumor suppressor/oncogene mutations in tumor development is clear, but the causes of the DNA sequence changes in human cancers are not. Although elegant experiments with transgenic mice harboring lacZ or cII target sequences show that exposure to mutagenic human carcinogens can cause base substitutions in vivo, it does not follow from this that the mutations found in human cancers have to be the direct result of damage by external mutagens. They could be due to endogenously generated reactive oxygen species, or polymerase infidelity, for example. Specific patterns of mutations in the defined sequence of a test system set up to address this question can provide information on the molecular events leading to DNA sequence changes in humans if the experimentally induced mutations and patient tumor mutations are compared in the same gene. Fortuitously, inactivating point mutations in the p53 gene are driving events in the immortalization of murine embryonic fibroblasts (MEFs) in vitro. This discovery offers a natural biological strategy for selecting p53 mutants. Immortalized cell lines arising from primary MEFs harboring human p53 sequences (Hupki, human p53 knock-in) have p53 mutations that match p53 mutations in human tumors.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 MutagenesisHome page
J. vom Brocke, A. Krais, C. Whibley, M. C. Hollstein, and H. H. Schmeiser
The carcinogenic air pollutant 3-nitrobenzanthrone induces GC to TA transversion mutations in human p53 sequences
Mutagenesis, September 2, 2008; (2008) gen049v1.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
D. Kandioler, G. Stamatis, W. Eberhardt, S. Kappel, S. Zochbauer-Muller, I. Kuhrer, M. Mittlbock, R. Zwrtek, C. Aigner, C. Bichler, et al.
Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer.
J. Thorac. Cardiovasc. Surg., May 1, 2008; 135(5): 1036 - 1041.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
V. M. Arlt, M. Stiborova, J. vom Brocke, M. L. Simoes, G. M. Lord, J. L. Nortier, M. Hollstein, D. H. Phillips, and H. H. Schmeiser
Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer
Carcinogenesis, November 1, 2007; 28(11): 2253 - 2261.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
V. M. Arlt, E. Frei, and H. H. Schmeiser
ECNIS-sponsored workshop on biomarkers of exposure and cancer risk: DNA damage and DNA adduct detection and 6th GUM-32P-postlabelling workshop, German Cancer Research Center, Heidelberg, Germany, 29-30 September 2006
Mutagenesis, January 1, 2007; 22(1): 83 - 88.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.